IMPORTANT SAFETY INFORMATIONPRESCRIBING INFORMATION

FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.

Modify FOLOTYN treatment by adjusting or omitting dose as needed1

  • Modified dosing may allow for the possibility of continued treatment in some patients
  • Dose modifications may help address the following toxicities, including in patients with severe renal impairment:
    • Mucositis
    • Hematologic toxicities
    • All other treatment-related toxicities
  • Based on patient tolerance, doses of FOLOTYN may be omitted or reduced. Omitted doses will not be made up at the end of the cycle; once a dose reduction occurs for toxicity, do not re-escalate

View dose modifications for:

Reference:

  • Folotyn [package insert]. Westminster, CO: Allos Therapeutics, Inc.